Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Journal of Molecular Biology|February 2, 2008
An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicitySandra M Lynch, Chun Zhou, Anne Messer
Behavioral Neuroscience|December 17, 2003
Exploratory activity and fear conditioning abnormalities develop early in R6/2 Huntington's disease transgenic miceValerie J Bolivar, Kevin Manley, Anne Messer
Journal of Parkinson'S Disease|November 26, 2013
Can intrabodies serve as neuroprotective therapies for Parkinson's disease? Beginning thoughtsMansi A Bhatt, Anne Messer, Jeffrey H Kordower
Expert Opinion on Biological Therapy|August 6, 2009
Developing intrabodies for the therapeutic suppression of neurodegenerative pathologyAnne Messer, Sandra M Lynch, David C Butler
Progress in Neurobiology|November 29, 2011
Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteinsDavid C Butler, Julie A McLear, Anne Messer
Biochimica Et Biophysica Acta|September 8, 2014
Antibodies and protein misfolding: From structural research tools to therapeutic strategiesErwin De Genst, Anne Messer, Christopher M Dobson
Brain Research|May 22, 2002
The development of behavioral abnormalities in the motor neuron degeneration (mnd) mouseValerie J Bolivar, J Scott Ganus, Anne Messer
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 27, 2004
A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synucleinChun Zhou, Sharareh Emadi, Michael R Sierks, et al.
Journal of Neuropathology and Experimental Neurology|September 15, 2010
Early or late-stage anti-N-terminal Huntingtin intrabody gene therapy reduces pathological features in B6.HDR6/1 miceAbigail Snyder-Keller, Julie A McLear, Tyisha Hathorn, et al.
Pageof 5